Comparative evaluation of the effects of hydrochlorothiazide and nebivolol versus hydrochlorothiazide and irbesartan on endothelial function in patients with newly diagnosed hypertension [VALUTAZIONE COMPARATIVA DEGLI EFFETTI SULLA FUNZIONE ENDOTELIALE DEL TRATTAMENTO CON NEBIVOLOLO E IDROCLOROTIAZIDE VS IRBESARTAN E IDROCLOROTIAZIDE IN PAZIENTI CON IPERTENSIONE ARTERIOSA NEO-DIAGNOSTICATA]

Trial Profile

Comparative evaluation of the effects of hydrochlorothiazide and nebivolol versus hydrochlorothiazide and irbesartan on endothelial function in patients with newly diagnosed hypertension [VALUTAZIONE COMPARATIVA DEGLI EFFETTI SULLA FUNZIONE ENDOTELIALE DEL TRATTAMENTO CON NEBIVOLOLO E IDROCLOROTIAZIDE VS IRBESARTAN E IDROCLOROTIAZIDE IN PAZIENTI CON IPERTENSIONE ARTERIOSA NEO-DIAGNOSTICATA]

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2012

At a glance

  • Drugs Hydrochlorothiazide; Irbesartan; Nebivolol
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Acronyms NINFE
  • Sponsors Laboratorios Menarini
  • Most Recent Events

    • 08 Mar 2012 Results published in the International Journal of Cardiology.
    • 27 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top